DGX Stock Analysis: Buy, Sell, or Hold?
DGX - Quest Diagnostics Inc.
$187.03
4.68 (2.57%)
▲
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 10, 2026
9d
Smart Money Distribution
DGX is up 3.3% this week, but smart money is buying puts. Top strike: $185 2026-03-20 with 552 OI. Put ratio: 89% View Scanner →
Strength: 5.6/10
Get Alerted When DGX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called DGX this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DGX shows positive signals but monitor for confirmation. Market pricing in 0.2% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: DGX shows positive signals but monitor for confirmation. Market pricing in 0.2% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$230.80
Based on 4.9% avg growth
INTRINSIC VALUE TODAY
$143.31
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DGX is currently trading at $187.03, which is considered extended relative to its 30-day fair value range of $174.91 to $185.32. The stock's valuation (Forward PE: 17.6) is in line with its historical norms (17.5). At these levels, the market is pricing in 0.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, DGX is showing sideways momentum. The price is approaching resistance at $191.07. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: DGX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DGX is showing sideways momentum. The price is approaching resistance at $191.07. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: DGX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$174.91 -
$185.32
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
66.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($198.38)
- NEUTRAL: Market pricing in 0.2% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$174.91 -
$185.32
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$7.34
(3.9%)
Support & Resistance Levels
Support Level
$179.73
Resistance Level
$191.07
Current Trend
Sideways
Fundamental Context
Forward P/E (Next Year Est.)
17.56
Wall Street Target
$198.38
(+8.8%)
Revenue Growth (YoY)
13.2%
Earnings Growth (YoY)
8.5%
Profit Margin
8.9%
Valuation Premium vs History
+0.2% premium
PE vs Historical
17.6 vs 17.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.2%
(market-implied from PE analysis)
1-Year Target
$182.71
(+0%)
2-Year Target
$183.08
(+0%)
3-Year Target
$183.45
(+1%)
3-Yr Target (if PE normalizes)
(PE: 18→18)
PE COMPRESSION
$182.81
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 5.8%)
$274.53
(+51%)
Base:
(SPY PE: 17.6, Growth: 5.8%)
$216.19
(+19%)
Bear:
(PE: 14.9, Growth: 5.8%)
$183.76
(+1%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (18x PE) as earnings recover.
Trailing PE: 21.47 | Current EPS (TTM): $8.51
Bull Case
$245.28
(+31%)
Analyst growth 22.0%, PE expands to 23.6
Base Case
$222.98
(+19%)
Market implied 22.0%, PE stable at 21.5
Bear Case
$124.26
(-34%)
Severe decline -20.0%, PE contracts to 18.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: January 30, 2026 9:58 PM ET
Data refreshes hourly during market hours. Next update: 10:58 PM
Data refreshes hourly during market hours. Next update: 10:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DGX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Gary M Pfeiffer
SELL
1482 shares
2025-10-22
Michael E Prevoznik
SELL
227 shares
2025-09-26
Michael E Prevoznik
SELL
175 shares
2025-09-24
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$653 | 47 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 57 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$121 | 62 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$263 | 47 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$257 | 58 HOLD |
Advanced DGX Option Strategies
Professional options setups generated by AI based on today's DGX price and gamma walls.
